Magnetic stimulation of the cerebellum for drug-resistant epilepsy
Tests magnetic stimulation of the cerebellum in adults with drug-resistant epilepsy.
Plain-language title generated from the registry record
Registry title: Long Term Efficacy and Safety of TMS Targeting Cerebellum to Treat DRE
Key facts
- Where
- Xi'an, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06832813, who can take part
Where in China
- Xijing hospitalXi'an, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xijing Hospital
- Trial code
- NCT06832813
- Record updated
- 3 April 2025
- Original description
This study aims to observe the long term efficacy and safety of cerebellar continuous θ burst stimulation (cTBS) for drug-resistant Epilepsy during enhanced and maintenance phase，in order to provide a new treatment for long-term control of drug-resistant epilepsy and improve the quality of life of those patients. A total of 100 patients with DRE will undergo cTBS treatment by precise navigation to bilateral cerebellar dentate nuclei. The frequency and clinical feature of seizures, scalp EEG，clinical score, MOCA，MMSE，and QOLIE-31 were ssessed at baseline, after 2 weeks of enhanced phase，8 weeks of consolidate phase, and 8 weeks of maintenance phase.Read full original descriptionShow less
Long Term Efficacy and Safety of Transcranial Magnetic Stimulation Targeting Cerebellum to Treat Drug-resistant Epilepsy During Enhanced and Maintenance Phase
This study aims to observe the long term efficacy and safety of cerebellar continuous θ burst stimulation (cTBS) for drug-resistant Epilepsy during enhanced and maintenance phase，in order to provide a new treatment for long-term control of drug-resistant epilepsy and improve the quality of life of those patients. A total of 100 patients with DRE will undergo cTBS treatment by precise navigation to bilateral cerebellar dentate nuclei. The frequency and clinical feature of seizures, scalp EEG，clinical score, MOCA，MMSE，and QOLIE-31 were ssessed at baseline, after 2 weeks of enhanced phase，8 weeks of consolidate phase, and 8 weeks of maintenance phase.
Inclusion: Age 18-65 years old，; Participants who are diagnosed as drug- resistant epilepsy,; Participants who has a history of DRE ≥2 years before enrollment，; Participants who has a seizure frequency of ≥2 seizures every month within 3 months before enrollment,; Participants and their families are aware of this study and sign informed consent.
Exclusion: Participants plan invasive therapy, such as operation,; Participants who are complicated with serious infection, cerebrovascular disease, malignant tumor and other nervous system diseases, with serious dysfunction of heart, liver, kidney and other organs, and with psychiatric disorders,; Participants who are in status epilepticus,; Participants who are in pregnancy or lactating,; Patients cannot tolerate repeated transcranial magnetic stimulation, or have contraindications of repeated transcranial magnetic stimulation.